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Abstract. Aminobisphosphonate aledronate is a compound 
commonly used clinically for the treatment of osteoporosis 
and other bone diseases, as a result of it preventing bone 
resorption. However, in previous years it has also been used 
to obtain cellular and animal models of a rare genetic disorder 
termed Mevalonate Kinase Deficiency (MKD). MKD is 
caused by mutations affecting the mevalonate kinase enzyme, 
in the cholesterol pathway and alendronate can be used to 
biochemically mimic the genetic defect as it inhibits farnesyl 
pyrophosphate synthase in the same pathway. Despite evidence 
in favor of the inhibition exerted on the mevalonate pathway, 
there is at least one clinical case of MKD in which alendronate 
improved not only skeletal and bone fractures, as expected, 
but also MKD clinical features. Based on this finding, the 
present study assessed the anti‑inflammatory properties of this 
aminobisphosphonate in vitro. No anti‑inflammatory effects 
of alendronate were observed in the in vitro experiments. 
Since MKD lacks specific treatments, these results may assist 
scientists and physicians in making the decision as to the most 
suitable choice of therapeutic compounds for this neglected 
disease.
Introduction
Alendronate (Ald), is a molecule belonging to the amino-
bisphosphonate family and is commonly used in the clinical 
treatment of osteoporosis and other bone disorders, including 
Paget's disease (1,2). Ald acts by reducing the resorptive 
activity and inducing accelerated programmed cell death 
of osteoclasts. Besides the well-known antibone resorption 
activity, the side effects of aminobisphosphonates have been 
investigated previously and contrasting findings report their 
pro-inflammatory effects, renal toxicity and adverse reac-
tion in the upper gastrointestinal tract of patients and animal 
models, although with certain differences depending on the 
compound and the type of administration (3-6).
These effects are caused, at a molecular level, by the 
inhibition of the farnesyl pyrophosphate synthase enzyme in 
the mevalonate pathway. The decreased number of prenylated 
GTP-binding proteins anchored to the membrane of osteo-
clasts (7,8) may induce apoptosis and therefore, reduce bone 
resorption.
Malfunctions in the post‑translational modification known 
as prenylation and the overproduction of several pro‑inflam-
matory cytokines, including IL-1β, are also suggested to be 
at the basis of Mevalonate Kinase Deficiency (MKD) (9). 
MKD is an autosomal recessively-inherited disease (OMIM 
#610377) caused by mutations in the MVK gene (12q24.11), 
which encodes the enzyme, mevalonate kinase (MK) in the 
mevalonate pathway (Fig. 1) (10-13).
Our previous studies developed cellular and animal 
models of MKD obtained following administration of the 
aminobisphosphonate, Ald or lovastatin (Lova). These inhibit 
the mevalonate pathway and allow partial reproduction of the 
biochemical defect characterizing patients with MKD (14,15).
However, Cantarini et al (16) described a case report 
in which Ald was administered to a patient with MKD to 
prevent skeletal and bone fractures and this treatment mark-
edly rescued the inflammatory symptoms and led to a disease 
remission period of several months (16). The positive effects 
of Ald suggested that this may be used as a potential thera-
peutic drug for MKD and not exclusively for bone disorders 
(16). However, this raises the issue of the apparently opposite 
roles of Ald in MKD. This aminobisphosphonate appears 
to exhibit contrasting effects, while having been reported 
to improve the clinical features of one patient, it has been 
extensively used to inhibit the mevalonate pathway in vivo 
and in vitro (14,15).
The intriguing observation that Ald antagonizes the 
pro‑inflammatory effects of the inhibited mevalonate pathway, 
prompted the present study to re-assess the activity of this 
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compound, using an MKD cellular model (murine Raw 264.7 
monocyte-macrophage cell line) and monocytes isolated from 
two patients with MKD.
Additionally, to avoid compound-dependent results and 
dissipate any question or controversy of the findings obtained, 
the pathway was inhibited using two different compounds, Ald 
and Lova. Once the pathway was inhibited, the acute phase 
was mimicked by administering a pro‑inflammatory stimulus, 
lipopolysaccharide (LPS), shortly followed by the therapeutic 
administration of Ald. The analysis of four pro‑inflammatory 
cytokines, interleukin (IL)-1α, IL-1β, IL-6 and tumor necrosis 
factor (TNF)-α, and programmed cell death (PCD), was used 
to assess the potential anti‑inflammatory effects of Ald on 
these cell models of MKD.
Materials and methods
Chemicals. Unless otherwise stated, the reagents were 
purchased from Sigma-Aldrich (Milan, Italy). LPS (E. coli 
serotype 055:B5; 1 mg/ml stock in H2O), Ald (30 mM) and 
Lova (50 mM) were dissolved in saline solution (Diaco SpA, 
Trieste, Italy).
Cell culture. The raw 264.7 cells (murine monocyte/macro-
phage cell line; Sigma-Aldrich) were cultured at 2.5x105 cells/ml 
in Dulbecco's modified Eagle's medium, supplemented with 
10% fetal bovine serum (FBS; Euroclone Spa, Milan, Italy) 
and 100 µM Ald or 20 µM Lova for 20 h at 37˚C in a 5% CO2 
incubator. Following incubation, 10 µg/ml LPS was added for 
an additional 24 h. Where appropriate, Ald was added at three 
different concentrations (25, 50 or 100 µM) together with LPS 
in order to analyze its potential anti‑inflammatory properties.
Two patients with MKD were diagnosed during the first 
year of life and followed-up at the Institute for Maternal and 
Child Health, IRCCS ‘Burlo Garofolo’, Trieste, Italy. The 
MKD diagnosis was confirmed by genetic analysis (Table I). 
These two patients were recruited to the present study at the 
age of 24 and 13. They had no recurrent infections and were 
not in the acute phase of the disease at the time of enrollment. 
The present study was approved by the ethical and scientific 
review board of the Institute for Maternal and Child Health, 
IRCCS ‘Burlo Garofolo’ (no. 185/8; 19/08/2008). For a child 
to be eligible, informed consent had to be obtained from 
the parents or caregivers. Monocytes were isolated from the 
two patients with MKD by selection with monoclonal CD14 
antibody (mouse IgG2a)-conjugated microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany), performed with 
manual columns, according to the manufacturer's instructions. 
The cells were subsequently cultured at 2.5x105 cells/ml in 
RPMI-1640 medium, containing 10% FBS (Euroclone Spa) 
and 1 µg/ml LPS for 24 h. As for the Raw 264.7 cells, 50 µM 
Ald was added together with LPS, where appropriate
At the end of the incubation periods, the supernatant was 
collected for the cytokine assay and the cells were pelleted for 
the PCD assay.
PCD assay. The PCD of the Raw 264.7 cells and the patient 
isolated monocytes were monitored by flow cytometry using 
double staining with Annexin V‑fluorescein isothiocyanate and 
propidium iodide (PI; Apoptosis Detection kit; Immunostep, 
Salamanca, Spain), according to the manufacturer's instruc-
tions. The fluorescence was measured with a Cyan ADP 
cytometer and Summit version 4.3 software (Beckman Coulter, 
Fort Collins, CO, USA), and was subsequently analyzed with 
FlowJo 7.6 software (TreeStar Inc., Ashland, OR, USA). This 
technique was used to assess the effect of the treatments on 
cell viability. Debris were excluded from the plot based on the 
scatter (FSC vs. SSC) and the apoptotic (Annexin V positive, 
A+; PI negative, PI- and positive, PI+) and the necrotic (A- and 
PI+) cells were characterized based on the fluorescence emitted.
Cytokine production assay. The analysis of four pro‑inflamma-
tory cytokines, IL-1α, IL-1β, IL-6 and TNF-α, was performed 
on culture medium from the Raw 264.7 cells and the patient 
isolated monocytes, using magnetic bead-based multiplex 
immunoassays (Bio-Plex; Bio-Rad Laboratories, Milano, 
Italy), according to the manufacturer's instructions. The data 
from the reactions were acquired using the Bio-Plex 200 
reader, a digital processor managed the data output and 
Bio-Plex Manager 6.0 software (Bio-Rad) presented data as 
the Median Fluorescence Intensity and concentration (pg/ml).
Table I. MVK gene mutations.
 
Patient Mutation
 
1 S135L/V377I
2 V377I/I268T
Figure 1. Schematic representation of the mevalonate pathway. The com-
pounds used in the present study are indicated at the side of the pathway. 
Treatment with alendronate and lovastatin biochemically inhibited the 
pathway.
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Statistical analysis. The statistical significance was calculated 
using one-way analysis of variance and Bonferroni post-hoc test 
correction in the case of multiple comparisons, using GraphPad 
Prism v5.0 software (GraphPad Software Inc., La Jolla, CA). 
The data are expressed as the mean ± standard deviation. P<0.05 
was considered to indicate a statistically significant difference.
Figure 2. Raw 264.7 cells were incubated with 100 µM Ald (left, grey) or 20 µM Lova (right, black) and subsequently with 10 µg/ml LPS and Ald 
(25, 50 or 100 µM). (A) The percentage of apoptotic cells was detected by positive Annexin V staining (A+) and the data are expressed as the mean ± standard 
deviation (B) The levels of IL-1α, IL-1β, IL-6 and TNF-α in the supernatant was assessed. The data are demonstrated as the percentage of levels compared to 
the standard value (100%). One-way analysis of variance and Bonferroni post-hoc test was performed for three independent experiments (*P<0.05, **P<0.01 
and ***P<0.001, compared with the untreated group). Ald, alendronate; Lova, lovastatin; LPS, lipopolysaccharide; ns, not significant.
Figure 3. Monocytes from patients with Mevalonate Kinase Deficiency were incubated with 1 µg/ml LPS and 50 µM Ald. (A) The percentage of apoptotic cells 
were determined by positive Annexin V (A+) staining. The data are expressed as the mean. (B) The levels of IL-1α, IL-1β, IL-6 and TNF-α in the supernatant 
were assessed. The data are demonstrated as the percentage of levels compared with LPS, considered as 100% of cytokine production in the respective 
experimental setting. One-way analysis of variance and Bonferroni post hoc test was performed for three independent experiments. LPS, lipopolysaccharide; 
Ald, alendronate; ns, non significant.
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Results
PCD. The Raw 264.7 cells demonstrated a statistically 
significant increase in PCD following the addition of a 
specific inhibitor (Ald or Lova) in addition to LPS. The 
Ald + LPS-treated or Lova + LPS-treated cells produced 
comparable results demonstrating that PCD was indepen-
dent of the compound used to inhibit the pathway (Fig. 2A). 
Additionally, the production of the pro‑inflammatory cyto-
kines, IL-1α, IL-1β, IL-6 and TNF-α, was not normalized by 
the presence of Ald, regardless of which inhibitor was previ-
ously used (Fig. 2B).
Anti‑inflammatory effect of Ald. In order to establish the 
potential anti-inflammatory effect of Ald, the drug was 
assessed at different concentrations (25, 50 and 100 µM) in the 
murine cellular model. No affect was observed at any concen-
tration with regards to the decrease of PCD or the secretion of 
pro‑inflammatory cytokines (Fig. 2A and B).
Therapeutic activity of Ald. The effects of Ald on monocytes 
isolated from two different patients with MKD (Table I) were 
assessed. Following the addition of the pro-inflammatory 
stimulus, LPS, the potential therapeutic activity of Ald was 
assessed. As previously observed in the murine cell line, Ald 
revealed no improvement in the PCD in the monocytes from 
the patients with MKD, however, increased the percentage of 
apoptotic cells (Fig. 3A).
Cytokine levels. The production levels of the cytokines 
IL-1α, IL-1β, IL-6 and TNF-α were determined in the super-
natant of the monocytes from the patients. The sensitivity 
of the specific human kit and their ranges were as follows: 
IL-1α (1.4-22569 pg/ml), IL-1β (3.2-3261 pg/ml), IL-6 
(2.3-28880 pg/ml) and TNF-α (5.8-95484 pg/ml). The results 
were in the range of the limits of quantification and therefore, 
the data obtained demonstrated the inefficacy of Ald treat-
ments in decreasing inflammation (P>0.05) (Fig. 3B).
Discussion
Despite the positive result described by Cantarini et al (16) 
in their case study, the present study failed to reproduce the 
anti‑inflammatory effects of Ald in vitro, using a murine cell 
line or monocytes isolated from two patients with MKD. By 
contrast, treatment with Ald continued to be associated with 
increased levels of PCD and the production of inflammatory 
cytokines, suggesting the lack of anti‑inflammatory activity 
for this compound, at least in vitro. A possible explanation for 
these contrasting findings may reside in the different back-
grounds of the MVK gene. Indeed, the patient described by 
Cantarini et al and the two patients in the present study carry 
different mutations, the first being homozygous for V377I (16) 
and the latter being compound heterozygous (S135L/V377I 
and I268T/V377I).
In addition, patients with MKD exhibit a heterogeneous 
clinical phenotype, characterized by recurrent episodes of 
fever, irritability, lymphadenopathy, abdominal pain, diarrhoea 
and skin rash, which differs in terms of intensity and frequency 
from one patient to the other. Additionally, patients with MKD 
also exhibit marked variability in the response to therapies 
(statins and biological drugs) designed to rescue the inflam-
matory phenotype (17-19). According to Hoffmann et al (20), 
it is inappropriate to administer statins and/or aminobisphos-
phonate to patients with MKD exhibiting a genetically 
determined inhibited mevalonate pathway. However, the same 
author, reported discordant effects following the administra-
tion of statins. Indeed, certain patients with MKD exhibited 
an improvement of the clinical features, while other patients 
exhibited detrimental effects, including a marked increase of 
febrile attacks (20).
Despite isolated cases in which a variety of compounds 
have been demonstrated to improve the symptoms exhibited by 
patients, MKD still lacks standardized and targeted therapies 
and remains a neglected and disease, without a recommended 
therapeutic agent. Since our previous study reported an in vitro 
model useful to assess aminobisphosphonates, it was suggested 
to physicians to perform in vitro assays on monocytes isolated 
from patients with MKD. Therefore, a preliminary evaluation 
of the proper anti‑inflammatory action of treatments may be 
obtained prior to treating patients themselves.
Being aware of all the limitations represented by cell 
models, in which the mevalonate pathway has been biochemi-
cally inhibited, the present study suggested that the in vitro 
model may contribute to identifying a common therapeutic 
strategy for patients with MKD.
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